UNSPSC 51142519: Brasofensine

This classification denotes an antiparkinsonian agent with the molecular formula C16H20Cl2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1YP2S94RVH, chemically known as 3-beta-(3,4-dichlorophenyl)-1-alpha-h, 5-alpha-h-tropane-2-alpha-carboxaldehyde (e)-(o-methyloxime). but generally known as brasofensine, which bears US NIH Compound Identifier 9554198. Brasofensine most often comes in base, maleate, and sulfate forms.

UNSPSC 51142519 Brasofensine, a Commodity code, does not align with the state and local procurement activity currently tagged under it. The three most recent opportunities associated with this code solicit naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products—none of which involve brasofensine, a pharmaceutical compound with a distinct therapeutic classification. The issuing bodies span state health agencies, county health departments, and cooperative purchasing alliances serving multiple jurisdictions, but their actual procurement focuses on opioid antagonists, prescription fulfillment infrastructure, and commodity pharmaceutical distribution rather than the specific active pharmaceutical ingredient this code nominally describes.

The geographic spread of recent activity includes Florida, Texas, and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) representing a multi-state purchasing vehicle. Seminole County, Florida released an IFB (IFB60459723LAS) on June 30, 2026, due July 26, 2023, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. MMCAP posted an RFP (S1070000015802) on January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers to state and local facilities across multiple states including Oregon. The mismatch between the brasofensine code and the actual solicitations suggests either a tagging error in the source data or that brasofensine procurement activity does not yet appear in recent state and local notices.